A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

PHASE3CompletedINTERVENTIONAL
Enrollment

1,016

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

June 13, 2023

Study Completion Date

June 13, 2023

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

GA Depot

Long acting intramuscular injection of glatiramer acetate, once every 4 weeks

OTHER

Placebo

IM injection once every 4 weeks

Trial Locations (112)

20007

Mapi Pharma Research site 12, Washington D.C.

33032

Mapi Pharma Research site 17, Homestead

33136

Mapi Pharma Research site 09, Miami

35058

Mapi Pharma Research site 11, Cullman

35209

Mapi Pharma Research site 08, Birmingham

43081

Mapi Pharma Research site 13, Westerville

48201

Mapi Pharma Research site 02, Detroit

60062

Mapi Pharma Research site 01, Northbrook

78681

Mapi Pharma Research site 04, Round Rock

80209

Mapi Pharma Research site 14, Denver

91105

Mapi Pharma Research site 15, Pasadena

Unknown

Mapi Pharma Research site 02, Homyel

Mapi Pharma Research site 04, Minsk

Mapi Pharma Research site 05, Minsk

Mapi Pharma Research site 06, Minsk

Mapi Pharma Research site 01, Vitebsk

Mapi Pharma Research site 07, Vitebsk

Mapi Pharma Research site 04, Banja Luka

Mapi Pharma Research site 06, Bihać

Mapi Pharma Research site 01, Sarajevo

Mapi Pharma Research site 03, Tuzla

Mapi Pharma Research site 14, Haskovo

Mapi Pharma Research site 10, Pazardzhik

Mapi Pharma Research site 01, Pleven

Mapi Pharma Research site 02, Pleven

Mapi Pharma Research site 03, Pleven

Mapi Pharma Research site 07, Pleven

Mapi Pharma Research site 12, Plovdiv

Mapi Pharma Research site 18, Rousse

Mapi Pharma Research site 04, Sofia

Mapi Pharma Research site 05, Sofia

Mapi Pharma Research site 06, Sofia

Mapi Pharma Research site 08, Sofia

Mapi Pharma Research site 11, Sofia

Mapi Pharma Research site 13, Sofia

Mapi Pharma Research site 15, Sofia

Mapi Pharma Research site 16, Sofia

Mapi Pharma Research site 19, Sofia

Mapi Pharma Research site 09, Veliko Tarnovo

Mapi Pharma Research site 17, Vratsa

Mapi Pharma Research site 01, Tallinn

Mapi Pharma Research site 01, Tbilisi

Mapi Pharma Research site 02, Tbilisi

Mapi Pharma Research site 03, Tbilisi

Mapi Pharma Research site 04, Tbilisi

Mapi Pharma Research site 05, Tbilisi

Mapi Pharma Research site 06, Tbilisi

Mapi Pharma Research site 07, Tbilisi

Mapi Pharma Research site 08, Tbilisi

Mapi Pharma Research site 09, Tbilisi

Mapi Pharma Research site 01, Safed

Mapi Pharma Research site 02, Tel Aviv

Mapi Pharma Research site 01, Chisinau

Mapi Pharma Research site 02, Chisinau

Mapi Pharma Research site 29, Barnaul

Mapi Pharma Research site 27, Bryansk

Mapi Pharma Research site 23, Chelyabinsk

Mapi Pharma Research site 01, Kazan'

Mapi Pharma Research site 19, Kemerovo

Mapi Pharma Research site 24, Krasnodar

Mapi Pharma Research site 03, Moscow

Mapi Pharma Research site 13, Moscow

Mapi Pharma Research site 14, Moscow

Mapi Pharma Research site 21, Moscow

Mapi Pharma Research site 25, Moscow

Mapi Pharma Research site 28, Moscow

Mapi Pharma Research site 02, Nizhny Novgorod

Mapi Pharma Research site 07, Nizhny Novgorod

Mapi Pharma Research site 10, Nizhny Novgorod

Mapi Pharma Research site 11, Novosibirsk

Mapi Pharma Research site 06, Perm

Mapi Pharma Research site 22, Pyatigorsk

Mapi Pharma Research site 08, Rostov-on-Don

Mapi Pharma Research site 09, Saint Petersburg

Mapi Pharma Research site 18, Saint Petersburg

Mapi Pharma Research site 20, Saint Petersburg

Mapi Pharma Research site 05, Samara

Mapi Pharma Research site 26, Saransk

Mapi Pharma Research site 15, Smolensk

Mapi Pharma Research site 16, Tyumen

Mapi Pharma Research site 04, Ufa

Mapi Pharma Research site 17, Ulyanovsk

Mapi Pharma Research site 32, Cherkasy

Mapi Pharma Research site 06, Chernihiv

Mapi Pharma Research site 11, Chernivtsi

Mapi Pharma Research site 03, Dnipro

Mapi Pharma Research site 04, Dnipro

Mapi Pharma Research site 24, Dnipro

Mapi Pharma Research site 18, Ivano-Frankivsk

Mapi Pharma Research site 26, Ivano-Frankivsk

Mapi Pharma Research site 27, Ivano-Frankivsk

Mapi Pharma Research site 09, Kharkiv

Mapi Pharma Research site 10, Kharkiv

Mapi Pharma Research site 08, Kherson

Mapi Pharma Research site 21, Kyiv

Mapi Pharma Research site 25, Kyiv

Mapi Pharma Research site 28, Kyiv

Mapi Pharma Research site 29, Kyiv

Mapi Pharma Research site 17, Lutsk

Mapi Pharma Research site 12, Lviv

Mapi Pharma Research site 13, Lviv

Mapi Pharma Research site 23, Lviv

Mapi Pharma Research site 05, Odesa

Mapi Pharma Research site 14, Poltava

Mapi Pharma Research site 34, Ternopil

Mapi Pharma Research site 31, Uzhhorod

Mapi Pharma Research site 16, Vinnitsa

Mapi Pharma Research site 01, Zaporizhzhya

Mapi Pharma Research site 02, Zaporizhzhya

Mapi Pharma Research site 07, Zaporizhzhya

Mapi Pharma Research site 20, Zaporizhzhya

Mapi Pharma Research site 33, Zhytomyr

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mapi Pharma Ltd.

INDUSTRY

NCT04121221 - A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS | Biotech Hunter | Biotech Hunter